Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions (LipoCol Forte): A Retrospective Cohort Study Based on a Real-World Database

References

• NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530. doi:10.1016/S0140-6736(16)00618-8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi:10.2337/dci18-0007.
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278(4):313–321. doi:10.1001/jama.1997.03550040069040
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742. doi:10.1016/S0140-6736(09)61965-6
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai, SRK, Welsh, P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564. doi:10.1001/jama.2011.860
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172(2):144–152. doi:10.1001/archinternmed.2011.625
   PubMed Web of Science ®Google Scholar
• Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. doi:10.1136/bmj.f2610
   PubMed Web of Science ®Google Scholar
• Danaei G, García Rodríguez LA, Fernandez Cantero O, et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236–1240. doi:10.2337/dc12-1756
   PubMedGoogle Scholar
• Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225–2232. doi:10.2337/dc13-2215
   PubMed Web of Science ®Google Scholar
• Herttua K, Martikainen P, Batty GD, et al. Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke. J Am Coll Cardiol. 2016;67(13):1507–1515. doi:10.1016/j.jacc.2016.01.044
   PubMed Web of Science ®Google Scholar
• Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830–839. doi:10.7326/0003-4819-150-12-200906160-00006
   PubMed Web of Science ®Google Scholar
• Yang CW, Mousa SA. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med. 2012;20(6):466–474. doi:10.1016/j.ctim.2012.07.004
   PubMed Web of Science ®Google Scholar
• Bogsrud MP, Ose L, Langslet G, et al. HypoCol (red yeast rice) lowers plasma cholesterol: a randomized placebo controlled study. Scand Cardiovasc J. 2010;44(4):197–200. doi:10.3109/14017431003624123
   PubMed Web of Science ®Google Scholar
• Moriarty PM, Roth EM, Karns A, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol. 2014;8(6):568–575. doi:10.1016/j.jacl.2014.09.002
   PubMed Web of Science ®Google Scholar
• Chen TL, Yeh CC, Lin CS, et al. Effects of red yeast rice prescription (LipoCol Forte) on adverse outcomes of surgery. QJM. 2019;112(4):253–259. doi:10.1093/qjmed/hcy278
   PubMed Web of Science ®Google Scholar
• Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1–16. doi:10.1016/j.phrs.2019.02.028
   PubMed Web of Science ®Google Scholar
• Olotu BS, Shepherd MD, Novak S, et al. Use of statins and the risk of incident diabetes: a retrospective cohort study. Am J Cardiovasc Drugs. 2016;16(5):377–390. doi:10.1007/s40256-016-0176-1
   PubMed Web of Science ®Google Scholar
• Ma T, Chang M-H, Tien L, et al. The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging. 2012;29(1):45–51. doi:10.2165/11597250-000000000-00000
   PubMedGoogle Scholar
• Lee J, Noh Y, Shin S, et al. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533–1543. doi:10.2147/TCRM
   PubMed Web of Science ®Google Scholar
• Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131–1149. doi:10.1002/pds.v25.10
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622. doi:10.1001/jama.279.20.1615
   PubMed Web of Science ®Google Scholar
• Ma T, Tien L, Fang C-L, et al. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–1983. doi:10.1016/j.clinthera.2012.08.004
   PubMed Web of Science ®Google Scholar
• Cheng C-L, Lee C-H, Chen P-S, et al. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24(6):500–507. doi:10.2188/jea.JE20140076
   PubMed Web of Science ®Google Scholar
• Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236–242. doi:10.1002/pds.v20.3
   PubMed Web of Science ®Google Scholar
• Liao CC, Lin CS, Shih CC, et al. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014;37(8):2246–2252. doi:10.2337/dc13-2957
   PubMedGoogle Scholar
• Duncan AJ, Hargreaves IP, Damian MS, et al. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicol Mech Methods. 2009;19(1):44–50. doi:10.1080/15376510802305047
   PubMed Web of Science ®Google Scholar
• Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol. 2008;19(6):553–557. doi:10.1097/MOL.0b013e3283168ecd
   PubMed Web of Science ®Google Scholar
• Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342–347. doi:10.1097/HCO.0b013e3283470359
   PubMed Web of Science ®Google Scholar
• Fang Y, Li W. Effect of Xuezhikang on lipid metabolism and islet b cell function in type II diabetes mellitus patients. J Capital Med. 2000;7(2):44–45.
   Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–2410. doi:10.1016/j.jacc.2016.02.071
   PubMed Web of Science ®Google Scholar
• Spigoni V, Aldigeri R, Antonini M, et al. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. Int J Mol Sci. 2017;18(7):7. doi:10.3390/ijms18071498
   Google Scholar
• Marazzi G, Cacciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther. 2011;28(12):1105–1113. doi:10.1007/s12325-011-0082-5
   PubMed Web of Science ®Google Scholar
• Tshongo Muhindo C, Ahn SA, Rousseau MF, et al. Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. Complement Ther Med. 2017;35:140–144. doi:10.1016/j.ctim.2017.10.014
   PubMedGoogle Scholar
• Cicero AFG, Fogacci F, Rosticci M, et al. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab. 2017;14:61. doi:10.1186/s12986-017-0214-2
   Google Scholar
• Becker DJ, French B, Morris PB, et al. Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J. 2013;166(1):187–196. doi:10.1016/j.ahj.2013.03.019
   PubMedGoogle Scholar
• Gordon RY, Cooperman T, Obermeyer W, et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware. Arch Intern Med. 2010;170(19):1722–1727. doi:10.1001/archinternmed.2010.382
   PubMed Web of Science ®Google Scholar
• Dujovne CA. Red yeast rice preparations: are they suitable substitutions for statins? Am J Med. 2017;130(10):1148–1150. doi:10.1016/j.amjmed.2017.05.013
   PubMed Web of Science ®Google Scholar
• Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24(13):1431–1434. doi:10.1177/2047487317715714
   PubMedGoogle Scholar
• Liao CC, Lin JG, Tsai CC, et al. An investigation of the use of traditional chinese medicine in stroke patients in taiwan. Evid Based Complement Alternat Med. 2012;2012:387164. doi:10.1155/2012/387164
   PubMedGoogle Scholar
• Fujimoto M, Tsuneyama K, Chen SY, et al. Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. Evid Based Complement Alternat Med. 2012;2012:892697. doi:10.1155/2012/892697
   PubMedGoogle Scholar